Bristol Lays Groundwork For First Dermatology Launch, Ahead Of TYK2 Inhibitor
The Company Will Begin Hiring A Sales Force
The company has not even filed the TYK2 inhibitor deucravacitinib for psoriasis, but Bristol will be a new player in a category dominated by entrenched rivals.
You may also be interested in...
The Belgium-headquartered firm has struggled of late to impress investors, most recently with data from its salt-inducible kinase inhibitors, and CMO Walid Abi-Saab told Scrip that one reason could be "the level of optimism that prevails in the company. We jump on things a bit ahead of time."
Private Company Edition: With $8.9bn raised in the second quarter, venture capital investment in biopharma companies reached its second highest quarterly total to date – behind only Q1 of this year. Also, Nimbus Therapeutics raised $105m and European drug developers get in on the VC action.
Finding good leaders always has been hard, but record-breaking VC investment and IPOs, COVID-19 and diversity initiatives have compounded the growing problem.